Can fluctuating estradiol during perimenopause affect mood symptoms?

Perimenopause is characterized by irregular estradiol variation rather than a simple linear decline. For some women—particularly those with other mood-risk factors—this hormonal variability is associated with greater depressive and negative-mood symptom burden.

Clinical evidence

• In an 8-week observational study of 50 symptomatic perimenopausal women, greater week-to-week estradiol variability was associated with higher depressive-symptom scores after adjustment for BMI, depression history, and stressful life events (β=0.11; 95% CI, 0.04–0.18).
• A separate weekly-sampling study likewise associated week-to-week estradiol increases with negative mood and depressive symptoms, especially among women with current depression.
• This is a vulnerability relationship, not a universal explanation: hormone–mood associations vary substantially between individuals, and some prospective studies have not found an association.

Mechanistic considerations

• Estradiol has credible serotonergic actions: it can influence serotonin synthesis through tryptophan hydroxylase, breakdown through monoamine oxidase, synaptic reuptake through the serotonin transporter (SERT), and serotonin-receptor expression.
• Human findings support estradiol sensitivity of serotonergic measures. Small PET studies in postmenopausal women reported reduced SERT binding following estradiol treatment. These results are consistent with a serotonergic pathway but do not establish that naturally fluctuating estradiol produces a specific, measurable serotonin change in an individual during perimenopause.

Factors shaping vulnerability

• Psychosocial stress, prior depression, and vasomotor symptoms each independently identify women at greater risk of depressive symptoms during the menopausal transition.
• Sleep disturbance and broader symptom patterns should be considered alongside cycle changes and mood; irritability may not follow the same estradiol-variability pattern as depressive symptoms.
• A single estradiol measurement is not useful for diagnosing perimenopause, because concentrations fluctuate substantially.

Bottom line

• Fluctuating estradiol is a scientifically supported contributor to depressive/negative-mood vulnerability in a subset of perimenopausal women, with serotonin-related signaling a biologically plausible—but indirectly supported—mechanism rather than a proven individual-level cause.